Morgan Stanley Maintains Hold Rating on Recursion Pharmaceuticals, Lowers Price Target
Morgan Stanley has maintained its 'Hold' rating on Recursion Pharmaceuticals (RXRX) while adjusting its price target to $5.60.
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Morgan Stanley has maintained its 'Hold' rating on Recursion Pharmaceuticals (RXRX) while adjusting its price target to $5.60.
Fortrea has introduced its new Feasibility Intelligence Engine (FINE), a platform designed to streamline cardiovascular trial delivery by consolidating historical and external data.
ACTO Technologies has launched its AI-driven roleplay solution, CxZone, within Veeva Vault CRM via X-Pages to assist life sciences field teams.
Filed: 2026-11-18 AccNo: 0001193125-26-466240 Size: 212 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Recursion Pharmaceuticals has reached an agreement with the FDA on the design of its registrational Phase 3 clinical trial for REC-4881, an investigational oral MEK1/2 inhibitor for treating familial adenomatous polyposis (FAP).
ICON plc has scheduled a live webinar titled 'De-Risking Immunotherapy Development: 5 Key Early Decisions' for December 7, 2026.